Abstract: FR-PO1018
The LMX1βR246Q Mutation Induces Podocyte Injury Through Dysregulation of Cholesterol Transport Gene Expression
Session Information
- Genetic Diseases of the Kidneys: Non-Cystic - II
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidney
- 1002 Genetic Diseases of the Kidney: Non-Cystic
Authors
- Hall, Gentzon, Duke University Medical Center, Durham, North Carolina, United States
- Ducasa, Gloria Michelle, University of Miami School of Medicine, Miami, Florida, United States
- Lane, Brandon M., Duke University, Durham, North Carolina, United States
- Lagas, Maxwell S., University of Arizona, Phoenix, Arizona, United States
- Kovalik, Maria Eugenia, Duke University, Durham, North Carolina, United States
- Gregory, Olivia G., Duke University, Durham, North Carolina, United States
- Wu, Guanghong, Duke University Medical Center, Durham, North Carolina, United States
- Chryst-Stangl, Megan, Duke University Medical Center, Durham, North Carolina, United States
- Wang, Liming, Duke University Medical Center, Durham, North Carolina, United States
- Spurney, Robert F., Duke University Medical Center, Durham, North Carolina, United States
- Fornoni, Alessia, University of Miami, Miami, Florida, United States
- Gbadegesin, Rasheed A., Duke University Medical Center, Durham, North Carolina, United States
Background
We previously reported a heterozygous missense mutation of the LIM Homeobox Transcription Factor 1 Beta (LMX1β) as a cause of nail-platella-like renal disease (NPLRD) in two families with hereditary FSGS. Currently, there are no targeted therapies for LMX1βR246Q-induced glomerulopathy. We hypothesized that LMX1βR246Q disrupts the expression of disease-relevant molecular targets within key signaling pathways that may be amenable to pharmacotherapy. To test this hypothesis, we performed an unbiased, whole-transcriptomic analysis in our established LMX1βWT and LMX1βR246Q-overexpressing podocyte lines to uncover potential therapeutic targets.
Methods
We conducted RNA-seq, qPCR, immunoblot, cholesterol efflux assays and apoptosis assays in our established LMX1βWT, LMX1βR246Q- and VIVIT overexpressing podocytes to evaluate the effect of the LMX1βR246Q mutation on cholesterol transport gene expression, cholesterol efflux and viability.
Results
Using RNA-seq, we determined that LMX1βR246Q-overexpressing podocytes express significantly reduced levels of ATP-binding Cassette Transporter Family A1 (ABCA1) and ABCG1 relative to LMX1βWT-overexpressing podocytes. These results were confirmed by qRCR. Protein expression of ABCA1 and ABCG1 was similarly reduced. Consistent with these findings, LMX1βR246Q-overexpressing podocytes displayed significantly increased lipid droplet accumulation, decreased basal and Apo-AI-stimulated cholesterol efflux and increased apoptosis relative to LMX1βWT-overexpressing podocytes. Evaluation of the putative promoter regions for ABCA1 and ABCG1 revealed no LMX1β binding sequences (i.e. FLAT-E or FLAT-F) but did reveal multiple candidate NFAT binding sequences. LMX1βR246Q-overexpressing podocytes displayed decreased NFAT4 expression and ABCA transporter expression was decreased in VIVIT-overexpressing podocytes.
Conclusion
The LMX1βR246Q mutation may cause FSGS, in part, through the dysregulation of NFAT-dependent lipid trafficking gene expression. This study provides the first demonstration of a potential role for impaired lipid trafficking in the pathobiology of familial FSGS and suggests that lipid depleting therapies may have a role in the treatment of some forms of familial FSGS.
Funding
- NIDDK Support